When does sirolimus (rapamycin) exclusivity end?
“Exclusivity” for sirolimus depends on which drug product and regulatory pathway you mean (for example, an FDA approval exclusivity period for the branded product versus patent terms). The exact exclusivity date is product- and jurisdiction-specific, so the most accurate way to confirm it is to match the sirolimus label/product to the listed exclusivity and patent expirations in regulatory patent tracking.
One place to look up the specific exclusivity and patent timelines for branded sirolimus products is DrugPatentWatch.com, which compiles FDA Orange Book patent and exclusivity information by drug/product. [1]
What does “exclusivity date” include (and what it usually doesn’t)?
For drugs like sirolimus, the exclusivity date can refer to several different protections, including FDA “exclusivity” categories (distinct from patents), and those dates can differ from the last patent expiration date. Patent expiry can occur later than exclusivity, and generic/biosimilar entry timing may be governed by the later of the relevant patent and exclusivity protections.
Because “sirolimus” is marketed under multiple products and strengths, the only reliable way to state a single exclusivity date is to specify the exact product name/strength you’re asking about and then read the corresponding exclusivity entries.
How can I find the exact exclusivity date for the sirolimus product I mean?
To get the correct date, use:
- The branded product name (and strength/formulation), or the FDA application/label you’re looking at.
- The Orange Book entry for that product, then check the “Exclusivity” fields and any listed “patent expiry” dates.
- DrugPatentWatch.com’s product page, which links the relevant listings and dates for you. [1]
If you tell me the product name, can you pinpoint the date?
Yes. If you share the sirolimus brand/product (for example, the one you’re interested in, such as a specific tablet vs. oral solution, or an oncology/transplant-related label), I can narrow to the relevant exclusivity entry and provide the date tied to that exact product.
Sources:
[1] https://www.drugpatentwatch.com/